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Abstract
The endogenous opioid system represents one of the principal systems in the modulation of pain. This has been
demonstrated in studies of placebo analgesia and stress-induced analgesia, where anti-nociceptive activity triggered by
pain itself or by cognitive states is blocked by opioid antagonists. The aim of this study was to characterize the effect of
opioid receptor blockade on the physiological processing of painful thermal stimulation in the absence of cognitive
manipulation. We therefore measured BOLD (blood oxygen level dependent) signal responses and intensity ratings to non-
painful and painful thermal stimuli in a double-blind, cross-over design using the opioid receptor antagonist naloxone. On
the behavioral level, we observed an increase in intensity ratings under naloxone due mainly to a difference in the non-
painful stimuli. On the neural level, painful thermal stimulation was associated with a negative BOLD signal within the
pregenual anterior cingulate cortex, and this deactivation was abolished by naloxone.
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Introduction
Nociceptive information processing and related pain perception
is subject to substantial facilitatory and inhibitory modulation [1].
Inhibitory mechanisms can alleviate pain under certain, often
cognitively or emotionally triggered, states [2] such as placebo [3]
and stress-induced analgesia [4]. Most importantly, both phenom-
ena point toward the importance of the endogenous opioid system
in pain modulation, as indicated by blockade of the effect in the
presence of the opioid antagonist naloxone [3,5,6]. Although basic
pain perception has been a topic of intense interest in functional
imaging [7,8], only more recently have the neuro-anatomical
networks underlying pain modulation also been investigated [9–
16]. The converging evidence from these studies on different
cognitive modulations of pain (e.g. attention, hypnosis, anticipa-
tion, feeling of control) points to the importance of the anterior
medial wall for pain modulation that seems to exert downstream
control via subcortical areas such as the amygdala and
periaqueductal grey. Interestingly, these activations greatly overlap
with brain areas with high opioid receptor density [12,16].
The aim of this study was to investigate the effect of opioid
receptor blockade on pain processing in the absence of any explicit
cognitive manipulation. Therefore, we investigated BOLD (blood
oxygen level dependent) responses and subjective ratings to painful
and non-painful contact heat stimuli with or without the
concomitant administration of the opioid receptor antagonist
naloxone using a double-blind, cross-over (i.e. within subject)
design. Based on previous data [17] we expected higher subjective
pain ratings under endogenous opioid receptor blockade (the
naloxone session) and a neural effect in areas that are involved in
pain processing and have a high density of opioid receptors such as
the anterior cingulate cortex (ACC), periaqueductal gray (PAG)
and amygdalae (AMG).
Methods
Subjects
A total of 20 subjects were recruited from the local community
(age: 29.364.8 years, right-handed, 10 men). Two subjects did not
complete the experiment; one subject had missing data due to a
technical failure and one subject had severe movement related
artifacts. This left a total of 16 subjects (8 men) for all analyses. All
subjects had normal pain thresholds at the site of stimulus
application, no history of pain and were not depressed (Beck’s
Depression Inventory, test scores were 9 or below, mean =2.1,
standard deviation =2.6). All procedures and methods were
approved by the local ethics committee, and all subjects gave
written informed consent.
Experimental Protocol
We employed a double-blind, cross-over, counter-balanced
design to test for the effect of naloxone on painful and non-painful
thermal stimuli. Of the 16 final subjects, 8 received naloxone
during the first session. The 2 experimental sessions (identical
except for treatment) were one week apart. The subjects were told
that on one of the two days they would receive an opioid receptor
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12344antagonist named naloxone, which might or might not change
their perception of the thermal stimuli. They were not told how
their perception might change.
We administered a bolus dose of 0.15 mg/kg naloxone
(Naloxon-ratiopharm, Ratiopharm, Ulm, Germany) or saline via
an i.v. line inserted into the antecubital vein of the left arm.
Because naloxone has a relatively short half-life (,70 min in blood
plasma; Summary of Product Characteristics, Ratiopharm) and its
clinically effective duration of action can be even shorter [18], we
also administered an intravenous infusion dose of 0.2 mg/kg/h
naloxone or saline (diluted in 250 ml of saline), starting shortly
after bolus administration. This dosing regime leads to a stable
concentration of naloxone in blood plasma over the length of the
experiment (see Figure S1) and is sufficient to block central opioid
receptors completely [19]. Note that previous studies using either
only an equivalent bolus dose [20] or an equivalent bolus dose in
combination with a lower infusion dose [10] have observed
reliable naloxone effects.
After receiving the bolus, the subject was then led into the
scanner. A 30630 mm thermode (peltier device, TSAII, Medoc,
Israel) was placed on the calf of the subject’s left leg and an fMRI
compatible mouse was placed in the subject’s right hand. We did
not measure skin temperature; all temperatures reported are those
entered into and monitored via the CoVAS program. First, the
pain threshold was determined using the method of limits [21].
Thresholds were obtained before and after each session with
ramped stimuli (1uC/s starting at a baseline of 32uC and with an
upper limit of 52uC to avoid tissue injury). Also before each
session, a randomized series of 6 thermal stimuli (43–48uC, plateau
duration 6 s) were administered for the subject to practice the
rating procedure. All thermal stimuli in the experiment (except
when determining threshold) started at a baseline temperature of
32uC and used a ramp rate of 10uC/s. The subjects rated the
thermal stimuli using a VAS (visual analogue scale) [22], a bar
presented using Presentation (http://www.neurobehavioralsystems.
com) and projected onto a mirror atop the head coil. The VAS had
an anchor at 0 (‘‘nothing perceived’’) and at 100 (‘‘unbearable
pain’’) with 50 marking the pain threshold. The color of the VAS
changed from yellow to red at 50, clearly demarcating the non-
painful scale and the pain scale.
Each fMRI session consisted of 40 trials and lasted 40–45
minutes. Each trial began with a reaction time task, followed by
the thermal stimulus, and ended with the rating procedure, in
which the subject rated the perceived intensity of the thermal
stimulus just received. The reaction time task, administered to
ensure vigilance, required the subject to watch a series of squares
in blue, green, yellow and red and press a button whenever the red
square appeared. A total of 20 squares for each trial were
presented randomly and each square appeared for 1 s. The
reaction time task was included to keep the subjects engaged
during the long pauses between thermal stimuli, included based on
[23]. After this 20 s task, a fixation cross appeared and eventually
blinked to indicate the beginning of the thermal stimulus portion
of the trial. The blink was embedded between a 3–5 s and 4–6 s
jitter. Following the second jitter, a trigger pulse was sent to the
thermode to start the thermal stimulus, which had a 6 s plateau.
Twelve seconds after the trigger pulse was sent to the thermode,
the VAS scale was presented for the subjects to rate. There was no
time limit to the rating procedure. This left an average of 62.1 s
(standard deviation =2.1 s, range 46.5–83.7 s) between consec-
utive thermal stimuli (Figure 1).
Based on a pilot study, four temperatures were used for the
thermal stimuli: 44uC was barely perceptible, 45.5uC was almost
at the pain threshold, 47uC was slightly above the pain threshold,
and 48uC was definitely above the pain threshold (pre-defined as a
VAS score of 50). The pilot study also demonstrated that the
perception of pain started 3–4 seconds after the trigger pulse was
sent to the thermode. Each of the 4 temperatures was presented 10
times in a pseudo-randomized order that was kept constant within
subjects (the subject was presented with the same randomization
for both the saline and naloxone sessions). The rating procedure
began 12 seconds after the trigger pulse was sent to the thermode.
During the thermal stimulation and until the VAS appeared, the
subjects saw a fixation cross. After the rating was entered, the
fixation cross reappeared for 5 s before the next trial.
Statistical Analysis of Behavioral Data
All statistical analyses of the behavioral data were done in
Matlab. Paired t-tests were used to test for the effect of treatment
on the intensity ratings and on general attention (reaction time
task). The significance threshold was set to 0.05.
Image data acquisition and processing
Subjects were scanned with a 3 T Siemens Trio using a T2*-
sensitive EPI sequence (TR =2.4 s, TE =25 ms, flip-angle 80u,
FoV 1926192 mm, 36363 mm voxel size) and an 8-channel
head-coil. SPM5 (http://www.fil.ion.ucl.ac.uk/spm) was used for
all pre-processing and statistical analyses of scans. Pre-processing
included slice-time correction to the middle slice, realignment,
spatial normalization to a standard EPI template and smoothing
with an 8 mm FWHM isotropic Gaussian kernel.
In order to compare the effect of treatment on pain, the thermal
stimuli were separated according to VAS rating score. The ‘‘non-
painful’’ category contained all stimuli rated 50 and below and the
‘‘painful’’ category contained all stimuli rated above 50, leading to
a2 62 (condition: non-painful and painful by treatment: naloxone
and saline sessions) factorial design.
All voxels within the brain were examined with a conventional
general linear model-based statistical analysis. For each individual,
the design matrix consisted of 5 regressors for each session. The
regressors were established by convolving a delta function for the
events or a box car for the blocks with the canonical hemodynamic
response function as implemented in SPM5. Time and dispersion
derivatives were also included for each regressor. The design
matrix modeled the following for each session: (1) non-painful
stimuli, (2) painful stimuli, (3) anticipation of a thermal stimulus
(blinking cross), (4) the 20 s blocks of the reaction time task and (5)
the button presses. As mentioned above, the time lapse between
trigger pulse and the subjective perception of pain was measured
in the pilot study and determined to be about 3 s. The onsets for
the non-painful and painful stimuli were therefore calculated as
the time of the trigger pulse plus 3 seconds.
Contrasts of interest were set up on the single subject level and
entered into a random effects analysis to examine activations
across subjects via a one sample t-test. We tested for the main
effect of intensity (painful stimuli minus non-painful stimuli), the
main effect of treatment (naloxone session minus saline session)
and the interaction of treatment and intensity (naloxone(painful –
non-painful) - saline(painful – non-painful)).
Correction was based on regions of interest comprising classical
pain areas (thalamus, insula, SII, SI and the mid-cingulate region,
for a review see [8], as well as areas known to be involved in
endogenous anti-nociception (ACC, PAG [12]). Small volume
correction was performed with templates constructed from the aal
(automated anatomical labeling) toolbox [24], except for the PAG,
for which the seed voxel from [9] was taken. All results are
reported at p,0.05 corrected for multiple comparisons.
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Behavioral
The average pain thresholds (6 standard deviation) before (pre-
session) and after (post-session) each session were 46.762.6uC and
49.560.8uC for saline and 47.462.1uC and 49.760.9uC for
naloxone (Table 1).
Under saline, an average (6standard deviation) of 2167 trials
were rated as non-painful (,=50 on the VAS) and 1967 trials
were rated as painful (.50 on the VAS). Under naloxone, 2166
trials were rated as non-painful and 1966 trials were rated as
painful (Table 1). The difference between the painful and non-
painful average VAS ratings of thermal stimuli was significantly
greater in the naloxone session as compared to the saline session
(one-tailed, T(15) =1.8, p,0.05). It should be noted that this
difference is driven by the non-painful stimuli. The average ratings
with standard error for each condition are listed in Table 1.
Although the intensity ratings of the men tended to be lower, there
Table 1. Summary of behavioral data.
SALINE NALOXONE
Pre-session Post-session Pre-session Post-session
Thresholds 46.762.6uC4 9 . 5 60.8uC 47.462.1uC 49.760.9uC
Non-painful Painful Non-painful Painful
Ratings 23.362.5 73.662.4 20.762.4 73.662.0
No. of Stimuli 21671 9 672 1 661 9 66
Pain thresholds were measured before (pre-session) and after (post-session) the
experimental session. The mean and standard deviation are given in degrees
Celsius.
The average ratings with standard error are in arbitrary units and categorized as
non-painful (VAS ,=50) or painful (VAS .50) for each treatment condition
(saline or naloxone). The average total number of stimuli for the particular
category with standard deviation for each category is listed under No. of Stimuli.
doi:10.1371/journal.pone.0012344.t001
Figure 1. Experimental paradigm. Each trial began with a reaction time (RT) task during which the subject had to press a button whenever a red
square appeared (arrow). The squares were presented randomly and appeared for 1 s. Thereafter, cross-hairs appeared and eventually blinked to
warn that a thermal stimulus was coming. The blink was sandwiched between a 3–5 s and 4–6 s jitter. Following the second jitter came the thermal
stimulus of 6 s (44uC, 45.5uC, 47uC, or 48uC) within a 12 s cross-hair presentation. The visual analogue rating (VAS) scale then appeared, which
consisted of two anchors at 0 ‘‘nothing’’ and 100 ‘‘intolerable pain’’ with a third anchor at 50 to mark the pain threshold. The subject could move the
edge of the right-hand side of the scale back and forth to the appropriate spot for as long as desired. The starting point of the VAS scale varied
randomly for each trial. Once a subject selected a position on the VAS, a cross-hair appeared for 5 s until the start of the next reaction time task.
doi:10.1371/journal.pone.0012344.g001
fMRI of Naloxone and Pain
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treatment sessions.
To check if naloxone had an effect on general attention, we
tested performance on the reaction time task (series of colored
squares) under naloxone and saline. Neither the reaction times nor
the miss rates (percentage of red squares not reacted to) were
significantly different across treatment sessions.
The reaction time task was included in the paradigm to offset
habituation and/or sensitization to the stimuli over the course of
the experiment [23]. We tested this by comparing the first half of
the session to the second half of the session for each temperature
within each treatment. There was no indication of habituation or
sensitization (Figure 2).
Imaging
Main effect of intensity. When comparing painful stimuli to
non-painful stimuli across treatment, several areas known to be
involved in pain processing showed significant activation. These
areas included bilateral insula, bilateral thalamus, bilateral
amygdala, bilateral basal ganglia and right (contralateral)
periaqueductal gray (Table 2 and Figure 3).
Treatment by intensity interaction. To test for a differential
response to thermal intensity dependent on treatment, we set up the
contrast (naloxone(painful – non-painful) - saline(painful – non-
painful)). The interaction analysis revealed a significant effect in the
anterior cingulate cortex (pregenual ACC: peak voxel in cluster
[215, 42, 12], Z =4.14, cluster size =61, p=0.007 small volume
FWE corrected, Table 2 and Figure 4 left). Specifically, under
physiologicalconditions(saline),anegativeBOLDresponsetopainful
stimulus intensity was observed, which was significantly reduced by
the administration of naloxone (Figure 4 right).
To further characterize the BOLD signal, we ran a finite
impulse response (FIR) analysis on the 12 second period between
thermal stimulus onset and rating procedure onset. Figure 5 shows
the negative BOLD signal under saline for the painful stimuli that
is blocked by naloxone for the peak voxel from the interaction of
treatment and intensity analysis [215, 42, 12].
Discussion
To investigate the role of the endogenous opioid system in
physiological pain processing, we combined painful and non-
painful thermal stimuli with a pharmacological intervention using
the opioid antagonist naloxone in a double-blind, cross-over
design. On the behavioral level, this led to an increased difference
between painful and non-painful ratings under naloxone; this
difference was driven by the difference in the non-painful ratings.
Functional neuroimaging revealed that painful thermal stimulation
leads to a negative BOLD signal within the pregenual ACC, which
is blocked by the administration of naloxone, suggesting an
inhibitory influence by endogenous opioids in this region.
Studies on opioid blockade in healthy human subjects have
yielded mixed results. Several studies do not find an effect of
naloxone on pain using either painful shocks [25], limb ischemia
Figure 2. Time course of ratings per temperature. The graph illustrates the average VAS score (6 sem) for the ten time points of each
temperature. Time point 1 would be the first time that temperature had been presented and time point 10 the last. A capital S indicates the saline
session and a capital N the naloxone session. 1 stands for 44uC, 2 for 45.5uC, 3 for 47uC and 4 for 48uC. To test for habituation or sensitization, we
compared the average rating over the second half of the session to the average rating over the first half of the session. There was no significant
difference for any temperature.
doi:10.1371/journal.pone.0012344.g002
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[28] studied the paradoxical thermal-grill, as well as heat- and
cold-induced pain. They found no effect of naloxone on any (heat,
cold, paradoxical) pain ratings.
However, other studies have successfully induced hyperalgesia
with naloxone. Earlier studies used dental post-operative pain
[6,29,30] or electric shocks [31], whereas a more recent study used
a combination of capsaicin and naloxone [32]. Yet another study
specifically targeted the mechano-insensitive nociceptors via
transdermal electrical stimulation and concluded that it is not
necessarily the magnitude of the perceived pain that is needed for
endogenous opioid release, but rather the activation of the
mechano-insensitive nociceptors [33]. This suggests that longer
and more intense pain stimuli more easily activate the opioid
Table 2. Imaging results for the main effect of intensity and for the interaction of treatment by intensity.
Region Coordinates Z-value voxel level P-value* SVC corrected
XYZ
Main Effect of Intensity
Insula 230 24 9 4.62 0.001
33 12 9 4.81 ,0.001
236 221 15 4.32 0.004
Thalamus 26 29 9 4.52 0.001
9 215 0 4.82 ,0.001
Amygdala 218 3 15 5.00 ,0.001
21 23 212 4.00 0.002
Caudate Nucleus 212 6 9 4.27 0.003
9 3 9 3.56 0.034
Globus Pallidus 212 3 23 3.94 0.003
9623 3.95 0.003
Putamen 18 12 9 4.20 0.004
PAG 6 218 23 4.78 0.001{
Interaction of Treatment by Intensity
Pregenual ACC 215 42 12 4.14 0.007
Main effect of intensity across treatment thresholded at p,0.001 uncorrected and small volume corrected (at p,0.001) using the AAL-template [24] for the region
listed, except for the PAG({), for which the seed voxel [3 221 23] from [9] was used. Treatment (naloxone vs saline session) by intensity (painful vs non-painful rating)
interaction. Small volume corrected using the AAL-template of the left anterior cingulate cortex. AAL = automated anatomical labeling, SVC = small volume corrected,
PAG = peri-aqueductal gray, ACC = anterior cingulate cortex *All p-values listed are family-wise-error corrected.
doi:10.1371/journal.pone.0012344.t002
Figure 3. Main effect of intensity on brain activation. Left: Activation (visualization threshold p,0.001 uncorrected) related to painful vs. non-
painful stimulus intensities across treatment, overlaid on the axial slice of a T1-weighted template image. The image shows bilateral activation in the
insula and thalamus; see Table 1 for a complete listing of results. The color bar represents t-values. Right: Plotted are the percent signal changes
(+sem) for the peak voxel in the right insula [33 12 9] for the 2 intensities (non-painful or painful) under each treatment condition (naloxone or saline
session). Percent signal change was computed using rfxplot [61].
doi:10.1371/journal.pone.0012344.g003
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12344Figure 4. Treatment by intensity interaction. Left: Results (visualization threshold p,0.001 uncorrected) related to the treatment (naloxone vs.
saline session) by intensity (painful vs. non-painful) interaction, overlaid on the axial slice of a T1-weighted template image. The image shows the
cluster around the peak voxel in the pregenual ACC. The color bar represents t-values. Right: Plotted are the percent signal changes (+sem) for the
peak voxel [215 42 12] for the intensities under each condition. Percent signal change was computed using rfxplot [61].
doi:10.1371/journal.pone.0012344.g004
Figure 5. FIR Analysis of the BOLD response in the pgACC. Finite Impulse Response (FIR) analysis of the BOLD response to non-painful and
painful thermal stimulation in the pregenual ACC for the peak voxel from the interaction analysis [215 42 12]. Peri-stimulus time is in scans. The
dashed lines demarcate the beginning and end of the thermal stimuli, including ramp-time (mean length 6 std, 3.6660.14 scans). The dash-dot line
demarcates the beginning of the VAS rating procedure.
doi:10.1371/journal.pone.0012344.g005
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mechano-insensitive nociceptors. However, aside from the elegant
studies by Koppert [33,34], no studies systematically examine
naloxone sensitive and naloxone insensitive pain using one type of
stimulus and dosing regimen.
In this study, the difference in intensity ratings between saline
and naloxone is driven by lower ratings for the non-painful stimuli
under naloxone. This is contrary to our hypothesis as we expected
higher intensities for the painful stimuli under naloxone to drive
the difference. To our knowledge, none of the studies that have
looked at non-painful thermal stimuli under naloxone and saline
have found a significant difference [28]. Interestingly, a study
looking at the effects of epidural morphine on somatosensory
functions found that the warm detection threshold was increased
by morphine; this effect was naloxone reversible [35].
We were interested in testing whether naloxone had an effect on
intensity ratings in general and on pain intensity ratings in
particular, in the absence of any cognitive or affective modulation.
The lack of a significant difference in pain intensity ratings in both
this within-subject design as well as in the control condition of a
between-subject placebo analgesia study by Eippert et al. [36]
might indicate that a cognitive/affective modulation is necessary
for naloxone to have a behavioral effect. However, there are
several studies showing an effect without such modulation. Borras
et al. [37] found an effect of naloxone on both pain and intensity
ratings during the latter half of a 24 s mild thermal stimulus,
Anderson et al. [32] found an effect using capsaicin coupled with
thermal stimuli and Koppert et al. [34] found an effect using
electrically induced pain. This indicates that there are several
factors which may lead to an effect of naloxone on subjective
ratings, including stimulus length, stimulus type as well as
cognitive/affective modulation.
Only one other study has looked at the effect of endogenous
opioid activity and pain on CNS activity through the use of
naloxone with fMRI [37]. By using long lasting thermal stimuli (25
seconds at 46uC), this study analyzed both behavioral and imaging
data as part of either an ‘‘early phase’’ (first 12 s) or a ‘‘late phase’’
(last 12 s). Across the total of four 46uC thermal stimuli, they
report a significant increase in the pain (intensity and unpleasant-
ness) ratings under naloxone only for the late phase. It is also in the
late phase that they find a difference between naloxone and saline
in the pregenual ACC and insula for mild thermal pain.
Borras et al. suggest that the second of the two-peaked BOLD
response (the late phase) represents regions involved in emotion
and that these are the regions affected by endogenous opioids. Our
design (phasic stimuli including both painful and non-painful
intensities) allows us to more cleanly delineate the neural response.
We are thereby able to show the influence of the endogenous
opioid system and the direction of activation in the pregenual
ACC due to increasing thermal intensity.
Our data showed a pain related deactivation of the rACC that
was blocked by the administration of naloxone, strongly suggesting
an activation of the endogenous opioid system. Consistent with our
finding, using opioid ligand PET, Sprenger et al. [38] were able to
show a decrease in opioid receptor binding after thermal pain
stimuli in the rACC, providing direct evidence for the involvement
of this region in the endogenous opioid inhibition of pain.
The rACC is strongly involved in the modulation of pain under
the control of cognitive strategies such as attention and placebo
analgesia. This region has also been characterized as showing a
high concentration of opioid receptors [39] and having a major
impact on opioidergic pain modulation [40]. Our data, implying
opioid release in the pregenual ACC coincident with painful
thermal stimulation, is therefore in line with these reports. The
rACC, however, is also closely linked to anxiety states [41] and
naloxone may be associated with an increase in anxiety and stress
levels [42,43]. Future studies with naloxone should consider
including measures of anxiety and stress.
We observed a distinct negative rather than positive BOLD
signal. This observation is in line with a recent fMRI study on
placebo analgesia that was able to dissociate areas that were either
activated or deactivated under the placebo as compared to the
control condition [36]. In agreement with our data, the neural
response to placebo in the pregenual ACC, and not the activation
in the subgenual ACC was most strongly modulated by naloxone.
In addition, this placebo analgesia-induced deactivation was
observed during the early and not the late phase of the 20 s
painful thermal stimulation, which is in agreement with the
stimulus duration of the thermal stimulus used in this study (6 s). In
line with these findings, a similar opiate dependent deactivation of
the ACC was observed in a study looking at exogenous opiate
administration without concomitant pain [44].
Opioid receptors are generally considered inhibitory receptors and
one could assume that binding of inhibitory receptors leads to
deactivation; however, molecular studies in rats show that opioid
receptor binding can lead to both inhibition and excitation. For
example, tonic inhibition courtesy of GABAergic-neurons can in turn
be inhibited by enkephalinergic neurons, leading to post-synaptic
excitation in the periaqueductal gray [45]. Concerning direct
inhibition, opiate administration leads to a decrease in extracellular
glutamate in the ACC [46] as well as in the PFC [47]. The decrease
in glutamate, an excitatory inhibitor, was in turn related to a decrease
in neuronal firing in these studies. Constellations of receptors and
neurotransmitters are highly heterogeneous between different
anatomical locations [45] and the binding of various agonists do
not parallel each other [48]. In addition, exogenous opiates and
endogenous opioid peptides differ at the molecular level leading to
variant cellular processes and finally systems level effects [49].
Recent investigations using fMRI have been able to show that
BOLD deactivations are tightly coupled to neuronal activity
[50,51]. Given that opioid receptors function via inhibitory
mechanisms [52], it is interesting to compare this system with
the effect of other inhibitory neurotransmitters such as GABA. A
recent functional neuroimaging study of the GABAergic system
has revealed negative BOLD signal changes in the pregenual ACC
in humans [53]. In light of these investigations, our finding of a
decrease in signal in conjunction with painful stimulus intensities is
likely due to opioidergic activity and fits in well with the
identification of opioid receptors as inhibitory receptors. Consid-
ering the close interaction between the GABAergic and opioider-
gic systems [54], it is also possible that the deactivation may be
directly mediated by GABA.
However, it should also be noted that some, mostly PET studies
have also reported opiate dependent activations in the ACC
[9,12,55–60]. Apart from the differences in stimulation and
imaging technique, one reason for this discrepancy might be
related to low spatial resolution in some studies, which would
collapse signals from functionally distinct ACC subareas. This
notion is supported by a recent study using considerably higher
spatial resolution fMRI and showing opiate dependent activation
and deactivation in neighboring ACC subregions during the same
condition [36].
In conclusion, our data reveals that the endogenous opioid
system is affected by thermal stimuli in the absence of any specific
cognitive manipulation. The hypothesis that endogenous opioids
lead to a deactivation of the pregenual ACC is supported by our
data showing that this effect can be blocked by the opioid receptor
antagonist naloxone.
fMRI of Naloxone and Pain
PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12344Supporting Information
Figure S1 Naloxone plasma concentrations: mean (+SEM) over
the 4 pilot subjects. Naloxone has a half-life of about 1 hour in
man [1]. Since the experiment lasted 1 hour, the concentration at
the end of the experiment would have substantially deviated from
the concentration at the beginning of the experiment had only a
bolus dose been given. Based on [1] and [2], the following
parameters were entered into AutoKinetic v3.4b, an MS-Excel-
based software for determining dosing strategies: one-compart-
ment model, the individual weight, a half-time of 1.1 h,
distribution volume of 2 L/kg. To keep the plasma concentration
of naloxone at 50 ng/ml, a dosing strategy of a bolus of 0.15 mg/
kg followed by 0.00347 mg/kg/min infusion was suggested. We
ran a pilot study with 4 men to test the strategy. References 1.
Goldfrank L, Weisman RS, Errick JK, Lo MW (1986) A dosing
nomogram for continuous infusion intravenous naloxone. Ann
Emerg Med 15: 566–570. 2. Baselt RC (2004) Disposition of Toxic
Drugs and Chemicals in Man, 7th Edition. Foster City:
Biomedical Publications. 802 p.
Found at: doi:10.1371/journal.pone.0012344.s001 (1.07 MB TIF)
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